Chronic Wounds - Pipeline Insight, 2024

This ''Chronic Wounds - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Wounds pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Wounds Understanding

A chronic Wounds is one that has failed to progress through the phases of healing in an orderly and timely fashion and has shown no significant progress toward healing in 30 days. Chronic Woundss are typically identified by a raised, hyperproliferative, yet non-advancing Wounds margin. The area around the Wounds will be inflamed and this inflammation may be affect healing negativity. Types of chronic Woundss may include, but are not limited to the following etiologies: venous ulcers, diabetic ulcers, and pressure ulcers.

Venous ulcers occur primarily in the legs of patients and are caused by problems with blood circulation due to dysfunctional blood valves or obstructed veins.

Diabetic ulcers often start as small scratches or bruises which patients with diabetes fail to notice due to nerve damage and limited sensitivity. Compromised immune systems and damaged capillaries lead to these formerly small and benign Woundss becoming dangerously infected.

Pressure ulcers primarily afflict patients who are bedridden or of limited mobility. The constant pressure on the tissue over powers the pressure of the capillaries, affecting blood flow. Areas at the greatest risk for pressure ulcers are the sacrum, shoulder blades and heels. Correctly identifying the cause of a chronic Wounds as well as the local and systemic factors that may be contributing to poor Wounds healing is critical to successful Wounds treatment.

Chronic Wounds - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Wounds pipeline landscape is provided which includes the disease overview and Chronic Wounds treatment guidelines. The assessment part of the report embraces, in depth Chronic Wounds commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Wounds collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Chronic Wounds. The therapies under development are focused on novel approaches to treat/improve Chronic Wounds.

Chronic Wounds Emerging Drugs

SkinTE: PolarityTE
SkinTE is a human cellular and tissue-based product derived from a patient's own skin intended for the repair, reconstruction, and replacement of skin tissue. SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products.

Chronic Wounds: Therapeutic Assessment

This segment of the report provides insights about the Chronic Wounds drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Wounds

There are approx. 5+ key companies which are developing the therapies Chronic Wounds. The companies which have their Chronic Wounds drug candidates in the most advanced stage, i.e Phase III include PolarityTE

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Wounds pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Wounds: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Wounds therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Wounds drugs.

Chronic Wounds Report Insights

• Chronic Wounds Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Wounds Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Wounds drugs?
• How many Chronic Wounds drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Wounds?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Wounds therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Wounds and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Layerbio
• PolarityTE
• Remedor Biomed

Key Products

• LB 210
• SkinTE
• Hydrogel Formulation

This product will be delivered within 2 business days.